PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  de Sutter, Johan ^a,b   van de Veire, Nico R ^a,c   Struyf, Sofie ^d   Philippé, Jan ^e   de Buyzere, Marc ^b   van Damme, Jo ^d  

^a AZ Maria Middelares Ghent ^*  (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CHEMOKINE; PLATLET FACTOR 4; PLATLET FACTOR 4 VARIANT; RANTES; UNCLASSIFIED DRUG; PF4V1 PROTEIN, HUMAN; THROMBOCYTE FACTOR 4;

ACUTE HEART FAILURE; ADULT; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; GENDER; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT; ALLELE; BLOOD; GENETICS; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; CHEMOKINE CCL5; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLATELET FACTOR 4; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84857578520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031343     Document Type: Article

References (30)

1. von Hundelshausen P, Petersen F, Brandt E, (2007) Platelet-derived chemokines in vascular biology. Thromb Haemost 97: 704-713.
2. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM, (2004) Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 95: 855-857.
3. Vandercappellen J, Van Damme J, Struyf S, (2011) The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev 22: 1-18.
4. Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, et al. (2007) Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67: 5940-5948.
5. Charo IF, Ransohoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
6. Coelho AL, Hogaboam CM, Kunkel SL, (2005) Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev 16: 553-560.
7. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, et al. (2009) Chemokines and chemokine receptors: an overview. Front Biosci 14: 540-551.
8. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, et al. (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197: 1537-1549.
9. Mueller A, Meiser A, McDonagh EM, Fox JM, Petit SJ, et al. (2008) CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol 83: 875-882.
10. Petersen F, Bock L, Flad HD, Brandt E, (1998) A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 161: 4347-4355.
11. Nesmelova IV, Sham Y, Gao J, Mayo KH, (2008) CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J Biol Chem 283: 24155-24166.
12. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, et al. (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 15: 97-103.
13. Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, et al. (2011) Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 117: 480-488.
14. Lazzeri E, Romagnani P, (2005) CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 5: 109-118.
15. Charo IF, Taubman MB, (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866.
16. Greinacher A, Althaus K, Krauel K, Selleng S, (2010) Heparin-induced thrombocytopenia. Hämostaseologie 30: 17-18.
17. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, et al. (2007) N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297: 169-176.
18. Van de Veire NR, De Winter O, Philippé J, De Buyzere M, Bernard D, et al. (2006) Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function. Am Heart J 152: 297.e1-7.
19. Vandercappellen J, Noppen S, Verbeke H, Put W, Conings R, et al. (2007) Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. J Leukoc Biol 82: 1519-1530.
20. Lasagni L, Grepin R, Mazzinghi B, Lazzeri E, Meini C, et al. (2007) PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 109: 4127-4134.
21. Han ZC, Bellucci S, Tenza D, Caen JP, (1990) Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura. Br J Haematol 74: 395-401.
22. Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, et al. (2007) Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood 110: 1153-1160.
23. Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, et al. (2003) Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 102: 146-151.
24. Scheuerer B, Ernst M, Durrbaum-Landmann I, Fleischer J, Grage-Griebenow E, et al. (2000) The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 95: 1158-1166.
25. Fricke I, Mitchell D, Petersen F, Böhle A, Bulfone-Paus S, et al. (2004) Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells. FASEB J 18: 1588-1590.
26. Gleissner CA, Shaked I, Little KM, Ley K, (2010) CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 184: 4810-4818.
27. Xia CQ, Kao KJ, (2003) Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells. Int Immunol 15: 1007-1015.
28. Woller G, Brandt E, Mittelstädt J, Rybakowski C, Petersen F, (2008) Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol 83: 936-945.
29. Rudiger A, Fischler M, Harpes P, Gasser S, Hornemann T, et al. (2008) In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. Int J Cardiol 126: 28-31.
30. Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, et al. (2010) Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 31: 3024-3031.